159 related articles for article (PubMed ID: 24147603)
1. Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos.
Asthana S; Gupta PK; Chaurasia M; Dube A; Chourasia MK
Expert Opin Drug Deliv; 2013 Dec; 10(12):1633-51. PubMed ID: 24147603
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of vesicular carriers for therapy of visceral leishmaniasis: conventional versus novel.
Kumar N; Gupta S; Dube A; Vyas SP
Crit Rev Ther Drug Carrier Syst; 2010; 27(6):461-507. PubMed ID: 21175419
[TBL] [Abstract][Full Text] [Related]
3. Nanostructured delivery systems with improved leishmanicidal activity: a critical review.
Bruni N; Stella B; Giraudo L; Della Pepa C; Gastaldi D; Dosio F
Int J Nanomedicine; 2017; 12():5289-5311. PubMed ID: 28794624
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Nanosystems and Strategies for Managing Leishmaniasis.
Vaghela R; Kulkarni PK; Osmani RAM; Bhosale RR; Naga Sravan Kumar Varma V
Curr Drug Targets; 2017; 18(14):1598-1621. PubMed ID: 27033193
[TBL] [Abstract][Full Text] [Related]
5. Development of nano-carriers for
Askarizadeh A; Badiee A; Khamesipour A
Expert Opin Drug Deliv; 2020 Feb; 17(2):167-187. PubMed ID: 31914821
[No Abstract] [Full Text] [Related]
6. Application of nanotechnology in treatment of leishmaniasis: A Review.
Akbari M; Oryan A; Hatam G
Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833
[TBL] [Abstract][Full Text] [Related]
7. Drug delivery strategies for therapy of visceral leishmaniasis.
Gupta S; Pal A; Vyas SP
Expert Opin Drug Deliv; 2010 Mar; 7(3):371-402. PubMed ID: 20201740
[TBL] [Abstract][Full Text] [Related]
8. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends.
Badiee A; Heravi Shargh V; Khamesipour A; Jaafari MR
Vaccine; 2013 Jan; 31(5):735-49. PubMed ID: 23219436
[TBL] [Abstract][Full Text] [Related]
9. A nanotechnology based new approach for chemotherapy of Cutaneous Leishmaniasis: TIO2@AG nanoparticles - Nigella sativa oil combinations.
Abamor ES; Allahverdiyev AM
Exp Parasitol; 2016 Jul; 166():150-63. PubMed ID: 27109311
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes.
Kar N; Chakraborty S; De AK; Ghosh S; Bera T
Eur J Pharm Sci; 2017 Jun; 104():196-211. PubMed ID: 28400285
[TBL] [Abstract][Full Text] [Related]
11. Colloidal drug carriers: achievements and perspectives.
Barratt G
Cell Mol Life Sci; 2003 Jan; 60(1):21-37. PubMed ID: 12613656
[TBL] [Abstract][Full Text] [Related]
12. Promising nanotherapy in treating leishmaniasis.
de Souza A; Marins DSS; Mathias SL; Monteiro LM; Yukuyama MN; Scarim CB; Löbenberg R; Bou-Chacra NA
Int J Pharm; 2018 Aug; 547(1-2):421-431. PubMed ID: 29886097
[TBL] [Abstract][Full Text] [Related]
13. Strategies for the design of orally bioavailable antileishmanial treatments.
Pham TT; Loiseau PM; Barratt G
Int J Pharm; 2013 Sep; 454(1):539-52. PubMed ID: 23871737
[TBL] [Abstract][Full Text] [Related]
14. Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis.
Kansal S; Tandon R; Dwivedi P; Misra P; Verma PR; Dube A; Mishra PR
J Antimicrob Chemother; 2012 Nov; 67(11):2650-60. PubMed ID: 22872448
[TBL] [Abstract][Full Text] [Related]
15. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
[TBL] [Abstract][Full Text] [Related]
16. Drug delivery: lessons to be learnt from Leishmania studies.
Shaw CD; Carter KC
Nanomedicine (Lond); 2014 Jul; 9(10):1531-44. PubMed ID: 25253500
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Role of Nanoparticles in Amphotericin B Delivery.
Zaioncz S; Khalil NM; Mainardes RM
Curr Pharm Des; 2017; 23(3):509-521. PubMed ID: 27799043
[TBL] [Abstract][Full Text] [Related]
18. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
19. Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies.
Asthana S; Gupta PK; Jaiswal AK; Dube A; Chourasia MK
Pharm Res; 2015 Aug; 32(8):2663-77. PubMed ID: 25715698
[TBL] [Abstract][Full Text] [Related]
20. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
